Figure 6.

PD-L1 FcIg/CD86 FcIg NP-functionalized MSCs effectively promote the development of MOG-specific T_reg cells in the MOG_35-55-EAE mouse model. a) Splenetic MOG-specific (i) T_h1, (ii) T_h17, and (iii) T_reg cells populations in EAE-inflicted mice 3 days after different prophylactic treatments (5 days p.i.). (n = 5) b) Splenetic MOG-specific (i) T_h1, (ii) T_h17, and (iii) T_reg cells populations in EAE-inflicted mice 3 days after different therapeutic treatments (5 days p.i.). MOG-specific (iv) T_h1, (v) T_h17 and (vi) T_reg cells, and (vii) antigen non-specific INF-γ⁺ cytotoxic T cell populations in the spinal cord of EAE-inflicted mice 3 days after different therapeutic treatments (21 days p.i.). (n = 5) c) Splenetic MOG-specific T_reg cells populations in EAE-inflicted mice 38 days p.i. after different prophylactic and therapeutic treatments. (n = 6) d) Representative anti-CD4- and anti-FoxP3-stained immunofluorescence images of spinal cord preserved from non-treated EAE-inflicted mice and different treated EAE-inflicted mice 38 days p.i. e) Prophylactic and therapeutic treatments with PD-L1 FcIg/CD86 FcIg LEF NP-functionalized MSCs in MOG_35-55-immunized mice with and without T_reg cell depletion. Mice in T_reg cell depletion groups received 3 intraperitoneal (i.p.) injections of anti-CD25 (200 μg per injection) before and after the treatments with the MSCs to achieve T_reg cell depletion. (iii) Time-dependent mean clinical scores of MOG_35-55-induced EAE inflicted mice after received different (i) prophylactic and (ii) therapeutic treatments. (iii) Cumulative EAE scores of MOG_35-55-EAE inflicted mice after received different treatments with and without T_reg cell depletion. (n = 6)